6533b85afe1ef96bd12b8b04

RESEARCH PRODUCT

AB0465 Etanercept therapy in rheumatoid arthritis patients with moderate or severe disease activity

subject

description

Background Rheumatoid arthritis (RA) is conventionally defined as moderate when the disease activity score assessed in 28 joints (DAS28) is ≥3.2, and high disease with DAS28 >5.1 Objectives Aim of this analysis was to evaluate the rate of remission and LDA (low disease activity), in RA patients starting etanercept therapy with moderate disease activity in the real world settings Methods The clinical records were retrospectively analysed from the Italian nationwide registry, called GISEA (Gruppo Italiano Studio Early Arthritis). RA patients with moderate (Mod-RA) and high (H-RA) disease activity (DAS28 >3.2) with incomplete response to conventional DMARDs and beginning a treatment with etanercept 50 mg/week subcutaneously (or 25 mg twice/week) over 10 years (2001-2010) were considered and compared. Clinical remission (DAS28 Results 963 patients with moderate to severe RA were selected. Out of 963, 320 had Mod-RA and 633 H-RA. At 1 year, the rate of patients achieving DAS28 remission were significantly higher in Mod-RA (47.9%) than in H-RA (24.5%, p Conclusions Consistently with previous reports, this preliminary data have provided evidence that in standard care setting Mod-RA patients had a high likelihood to achieve a DAS28 driven clinical remission as well as a condition of LDA when treated with etanercept Disclosure. This analysis was supported by Pfizer Inc. Disclosure of Interest F. Iannone Grant/Research support from: Pfizer Inc., G. Ferraccioli: None Declared, C. Ferri: None Declared, M. Galeazzi: None Declared, R. Gerli: None Declared, R. Giacomelli: None Declared, W. Grassi: None Declared, R. Gorla: None Declared, M. Govoni: None Declared, A. Marchesoni: None Declared, L. Punzi: None Declared, P. Sarzi-Puttini: None Declared, G. Triolo: None Declared, G. Lapadula: None Declared